Race Initiates FTO Biomarker Research Collaboration with Chaim Sheba Israel
27 October 2021 – Race Oncology Limited (“Race”) is pleased to announce it has entered…
Welcome to our Investor page. Here you will find information on the latest ASX announcements, investor presentations and other shareholder information on Race Oncology.
ASX Announcements
Share Price
Latest News
Race secures sixth US patent for Zantrene
United States Patent No. 11,147,800 entitled COMBINATORIAL METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF BISANTRENE…
Race secures fifth US patent for Zantrene
Race Oncology (“Race”) is pleased to announce that it has been issued a new patent…
Zantrene kills melanoma cancer cells that overproduce FTO
Zantrene at low concentrations kills high FTO producing melanoma cancer cellsSensitivity to Zantrene correlates with…
First Patient Dosed in Phase 1b/2 AML Trial at Chaim Sheba Medical Center Israel
09 August 2021 – Race Oncology Limited (“Race”) is pleased to announce that the first…
Race Commences Phase 1b/2 AML Trial at Chaim Sheba Israel
22 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed…
